^
    Back
    Association details:
    Biomarker:MET positive
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor) +
    emibetuzumab (LY2875358) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lung Cancer
    Title:

    A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

    Published date:
    03/17/2022
    Excerpt:
    One hundred and eleven MET+ patients received emibetuzumab plus erlotinib (N = 83) or emibetuzumab monotherapy (N = 28). 89 of 111 MET+ samples were post-erlotinib....Disease control rate and progression-free survival were higher for emibetuzumab plus erlotinib (50%/3.3 months) than for emibetuzumab (26%/1.6 months).
    DOI:
    10.1016/j.cllc.2022.03.003